Oncologie, a Boston and Shanghai based innovative biopharmaceutical company, raised $16.5M in seed funding.
The round was led by Pivotal bioVenture Partners China, and joined by Nan Fung Life Sciences, China Merchant Bank Investments and Volcanics Ventures.
Led by Founder, President, and CEO Dr. Laura Benjamin, Oncologie is developing cancer therapies to improve long-term survival of patients worldwide.
Building a pipeline of clinical stage drug candidates through licensing and partnering, the company is leveraging the recent regulatory changes in China to conduct parallel clinical development in the country and the US to bring innovative Immuno-Oncology products to the two markets simultaneously.
Oncologie is developing multiple global programs currently in Phase 2 and Phase 3 whose mechanisms are designed to combine with immune checkpoint inhibitors to improve survival benefits.